Elraglusib is under clinical development by Actuate Therapeutics and currently in Phase II for Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF).
Risk Adjusted Net Present Value: What is the current valuation of Pfizer’s PF-07264660
The revenue for PF-07264660 is expected to reach an annual total of $14 mn by 2039 in the US based off GlobalData’s Expiry Model. The